Unison, an independent private equity firm with operations in Japan, Korea, and Singapore, agreed to acquire Kyowa, which develops, manufactures and sells branded and generic pharmaceutical products, from Lupin, a pharmaceutical company, for $526m. “We are very pleased to partner with Unison, a leading healthcare-focused private equity player. This transaction will build upon the strong foundation our team has established in Japan. We acquired Kyowa in 2007 and since then have made a material difference to the Japanese healthcare system with the affordable medicines we brought to the market. This transaction is aligned with our vision to focus on our key markets and strategic priorities to achieve sustainable growth in the mid to long-term. The deal proceeds will be utilized to strengthen Lupin’s balance sheet as well as provide growth capital to support organic and inorganic initiatives for our focus markets,” Vinita Gupta, Lupin CEO.